Taxanes for the treatment of metastatic breast cancer

Research output: Contribution to journalReview article

44 Scopus citations

Abstract

Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early-and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albuminbound formulation that enhances delivery of paclitaxel to tumors, in the management of metastatic breast cancer (MBC). Since the introduction of Cremophor EL-paclitaxel to the clinic in the mid-1990s, a substantial amount of investigation has gone into subjects such as formulation, dose, schedule, and taxane resistance, allowing physicians greater flexibility in treating patients with MBC. This review will also examine how the shrinking pool of taxane-naive patients, a result of the expansion of taxanes into the neoadjuvant and adjuvant settings, will respond to taxane retreatment for metastatic disease. Taxane treatment seems likely to continue to play an important role in the treatment of MBC.

Original languageEnglish (US)
Pages (from-to)159-171
Number of pages13
JournalBreast Cancer: Basic and Clinical Research
Volume6
Issue number1
DOIs
StatePublished - Nov 12 2012

Keywords

  • Docetaxel
  • Metastatic breast cancer
  • Nab-paclitaxel
  • Paclitaxel
  • Taxanes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Taxanes for the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this